Trials / Terminated
TerminatedNCT03327727
VL-2397 Compared to Standard First-Line Treatment for Invasive Aspergillosis (IA) in Adults
A Phase 2 Study of VL-2397 Compared to Standard First-Line Treatment for Invasive Aspergillosis in Adults With Acute Myelogenous Leukemia, Acute Lymphocytic Leukemia, or Allogeneic Hematopoietic Cell Transplant Recipients
- Status
- Terminated
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 4 (actual)
- Sponsor
- Vical · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of the trial is to evaluate the safety and efficacy of a new antifungal with a novel mechanism of action in immunocompromised adults with invasive aspergillosis.
Detailed description
To compare the safety and efficacy of VL-2397 to standard first-line treatment for invasive aspergillosis in immunocompromised adults with acute leukemia or recipients of an allogeneic hematopoietic cell transplant (allo-HCT).
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Investigational Agent: VL-2397 | VL-2397 |
| DRUG | Standard treatment: Voriconazole, Isavuconazole, or Liposomal amphotericin B | Voriconazole, Isavuconazole, or Liposomal amphotericin B |
Timeline
- Start date
- 2018-02-20
- Primary completion
- 2019-01-14
- Completion
- 2019-01-14
- First posted
- 2017-10-31
- Last updated
- 2019-02-27
Locations
28 sites across 6 countries: United States, Belgium, Canada, France, Germany, South Korea
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT03327727. Inclusion in this directory is not an endorsement.